Searle & Co’s Royalty Pharma RPRX Stock Holding History

Searle & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.22M	Buy	57,500 +1,000	+2%	+$52K	0.72%	40
2026 Q1	$2.71M	Sell	56,500 -1,000	-2%	-$43.8K	0.68%	40
2025 Q4	$2.22M	Hold	57,500	–	–	0.57%	47
2025 Q3	$2.03M	Hold	57,500	–	–	0.54%	52
2025 Q2	$2.07M	Hold	57,500	–	–	0.59%	49
2025 Q1	$1.79M	Hold	57,500	–	–	0.51%	57
2024 Q4	$1.47M	Hold	57,500	–	–	0.42%	58
2024 Q3	$1.63M	Hold	57,500	–	–	0.41%	56
2024 Q2	$1.52M	Buy	+57,500	New	+$1.59M	0.36%	64

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Searle & Co's RPRX Position: Q2 2026 in Review

Searle & Co increased its Royalty Pharma (RPRX) stake by 1.8% in Q2 2026, buying an estimated $52K and bringing the position to 57,500 shares worth $3.22M. The position accounts for 0.72% of the portfolio, ranked #40.

Searle & Co first reported a position in RPRX in Q2 2024 and has held it in 9 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Searle & Co held 57,500 shares of Royalty Pharma worth $3.22M as of Q2 2026.
Searle & Co bought 1,000 Royalty Pharma shares in Q2 2026, an estimated $52K.
Royalty Pharma made up 0.72% of Searle & Co's portfolio in Q2 2026, its #40 holding.
Searle & Co first reported a position in Royalty Pharma in Q2 2024 and has held it in 9 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Searle & Co's 13F filing for Q2 2026, filed 27 Jul 2026.